Sign In
Buy PRTA
$8.92
-0.270 (-2.94%)
At Close: Jun 03, 2026
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
04:24pm, Friday, 06'th May 2022 Zacks Investment Research
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
01:33pm, Friday, 06'th May 2022
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
10:35pm, Thursday, 05'th May 2022 Zacks Investment Research
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates
08:19pm, Thursday, 05'th May 2022
Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
12:43pm, Thursday, 05'th May 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer
The�
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
07:44pm, Monday, 02'nd May 2022 Benzinga
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in
Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock
03:49pm, Monday, 02'nd May 2022
RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in
10 Biggest Price Target Changes For Monday
12:36pm, Monday, 02'nd May 2022 Benzinga
Morgan Stanley boosted Archer-Daniels-Midland Company (NYSE: ADM) price target from $69 to $94. Archer-Daniels-Midland shares fell 0.5% to $89.10 in pre-market trading.
RBC Capital cut the price tar
Prothena (PRTA) IND Application Gets FDA Clearance for AD
03:44pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Prothena (PRTA) IND Application Gets FDA Clearance for AD
12:48pm, Tuesday, 29'th Mar 2022
Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
12:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protei
Prothena to Participate in Stifel 2022 Virtual CNS Days
08:05pm, Monday, 21'st Mar 2022 GlobeNewswire Inc.
DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built
Prothena Highlinghts New Preclinical Data For Alzheimer''s, Parkinson''s Vaccine Programs
01:20pm, Wednesday, 16'th Mar 2022 Benzinga
Prothena Corporation plc (NASDAQ: PRTA ) presented new preclinical data from its dual Aβ/tau and tandem C-terminal α-synuclein vaccine programs in Alzheimer''s disease (AD) and Parkinson''s disease (PD), respectively. The data were presented at the International Conference on … Full story available on Benzinga.com
PRTA stock lower amid plans for IND filing for Alzheimer’s candidate (NASDAQ:PRTA)
11:25am, Wednesday, 16'th Mar 2022 Seeking Alpha
Announcing preclinical data for its dual Aβ/tau vaccine targeted at Alzheimer’s disease, clinical-stage biotech Prothena Corporation (PRTA) said on Wednesday that the company plans for…
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
09:30am, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
DUBLIN, Ireland, March 16, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o
